Novartis Agrees to Acquire Excellergy, Inc., Building on Allergy Leadership with Next-Generation Anti-IgE Innovation
Novartis today announced that it has entered into an agreement to acquire Excellergy, Inc., a private biotech company developing next-generation anti-IgE therapies for IgE-driven diseases. The proposed acquisition adds Exl-111, a half-life extended, high-affinity anti-IgE antibody in Phase 1. The acquisition builds on deep Novartis expertise in IgE biology and a long-standing presence in allergic […]
